SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Bradley J. A.) "

Sökning: WFRF:(Bradley J. A.)

  • Resultat 231-240 av 295
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
231.
  • Staedele, Veronika, et al. (författare)
  • The complex Y-chromosomal history of gorillas
  • 2022
  • Ingår i: American Journal of Primatology. - : John Wiley & Sons. - 0275-2565 .- 1098-2345. ; 84:3
  • Tidskriftsartikel (refereegranskat)abstract
    • Studies of the evolutionary relationships among gorilla populations using autosomal and mitochondrial sequences suggest that male-mediated gene flow may have been important in the past, but data on the Y-chromosomal relationships among the gorilla subspecies are limited. Here, we genotyped blood and noninvasively collected fecal samples from 12 captives and 257 wild male gorillas of known origin representing all four subspecies (Gorilla gorilla gorilla, G. g. diehli, G. beringei beringei, and G. b. graueri) at 10 Y-linked microsatellite loci resulting in 102 unique Y-haplotypes for 224 individuals. We found that western lowland gorilla (G. g. gorilla) haplotypes were consistently more diverse than any other subspecies for all measures of diversity and comprised several genetically distinct groups. However, these did not correspond to geographical proximity and some closely related haplotypes were found several hundred kilometers apart. Similarly, our broad sampling of eastern gorillas revealed that mountain (G. b. beringei) and Grauer's (G. b. graueri) gorilla Y-chromosomal haplotypes did not form distinct clusters. These observations suggest structure in the ancestral population with subsequent mixing of differentiated haplotypes by male dispersal for western lowland gorillas, and postisolation migration or incomplete lineage sorting due to short divergence times for eastern gorillas.
  •  
232.
  • Ungar, Leo, et al. (författare)
  • Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes : Insights From the TRACER Trial
  • 2018
  • Ingår i: Journal of the American Heart Association. - 2047-9980 .- 2047-9980. ; 7:24
  • Tidskriftsartikel (refereegranskat)abstract
    • BackgroundVorapaxar, a protease‐activated receptor‐1 antagonist, is approved for secondary prevention of cardiovascular events but is associated with increased intracranial hemorrhage.Methods and ResultsTRACER (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome) was a trial of vorapaxar versus placebo among patients with acute coronary syndrome. Strokes were adjudicated by a central events committee. Of 12 944 patients, 199 (1.5%) had ≥1 stroke during the study period (median follow‐up, 477 days). Four patients had a single stroke of unknown type; 195 patients had ≥1 stroke classified as hemorrhagic or nonhemorrhagic (165 nonhemorrhagic, 28 hemorrhagic, and 2 both). Strokes occurred in 96 of 6473 patients (1.5%) assigned vorapaxar and 103 of 6471 patients (1.6%) assigned placebo. Kaplan‐Meier incidence of stroke for vorapaxar versus placebo was higher for hemorrhagic stroke (0.45% versus 0.14% [hazard ratio, 2.74; 95% confidence interval, 1.22–6.15]), lower but not significantly different for nonhemorrhagic stroke (1.53% versus 1.98% at 2 years [hazard ratio, 0.79; 95% confidence interval, 0.58–1.07]), and similar for stroke overall (1.93% versus 2.13% at 2 years [hazard ratio, 0.94; 95% confidence interval, 0.71–1.24]).ConclusionsStroke occurred in <2% of patients. Vorapaxar‐assigned patients had increased hemorrhagic stroke but a nonsignificant trend toward lower nonhemorrhagic stroke. Overall stroke frequency was similar with vorapaxar versus placebo.
  •  
233.
  • van Rheenen, Wouter, et al. (författare)
  • H63D polymorphism in HFE is not associated with amyotrophic lateral sclerosis
  • 2013
  • Ingår i: Neurobiology of Aging. - : Elsevier BV. - 0197-4580 .- 1558-1497. ; 34:5, s. 1517.e5-1517.e7
  • Tidskriftsartikel (refereegranskat)abstract
    • The H63D polymorphism in HFE has frequently been associated with susceptibility to amyotrophic lateral sclerosis (ALS). Regarding the role of HFE in iron homeostasis, iron accumulation is considered an important process in ALS. Furthermore, novel therapeutic strategies are being developed targeting this process. Evidence for this genetic association is, however, limited to several small studies. For this reason we studied the H63D polymorphism in a large European cohort including 3962 ALS patients and 5072 control subjects from 7 countries. After meta-analysis of previous studies and current findings we conclude that the H63D polymorphism in HFE is not associated with susceptibility to ALS, age at disease onset, or survival. (C) 2013 Elsevier Inc. All rights reserved.
  •  
234.
  •  
235.
  •  
236.
  • Welch, Brian, et al. (författare)
  • JWST Imaging of Earendel, the Extremely Magnified Star at Redshift z=6.2
  • 2022
  • Ingår i: Astrophysical Journal Letters. - : Institute of Physics (IOP). - 2041-8205 .- 2041-8213. ; 940
  • Tidskriftsartikel (refereegranskat)abstract
    • The gravitationally lensed star WHL 0137-LS, nicknamed Earendel, was identified with a photometric redshift z (phot) = 6.2 +/- 0.1 based on images taken with the Hubble Space Telescope. Here we present James Webb Space Telescope (JWST) Near Infrared Camera images of Earendel in eight filters spanning 0.8-5.0 mu m. In these higher-resolution images, Earendel remains a single unresolved point source on the lensing critical curve, increasing the lower limit on the lensing magnification to mu > 4000 and restricting the source plane radius further to r < 0.02 pc, or similar to 4000 au. These new observations strengthen the conclusion that Earendel is best explained by an individual star or multiple star system and support the previous photometric redshift estimate. Fitting grids of stellar spectra to our photometry yields a stellar temperature of T (eff) similar to 13,000-16,000 K, assuming the light is dominated by a single star. The delensed bolometric luminosity in this case ranges from log(L)=5.8 L-theta, which is in the range where one expects luminous blue variable stars. Follow-up observations, including JWST NIRSpec scheduled for late 2022, are needed to further unravel the nature of this object, which presents a unique opportunity to study massive stars in the first billion years of the universe.
  •  
237.
  •  
238.
  • Wu, R, et al. (författare)
  • Adaptive ground bounce removal
  • 2001
  • Ingår i: IEEE Electronics Letters. ; 37, s. 1250-1252
  • Tidskriftsartikel (refereegranskat)
  •  
239.
  • Yeap, Bu B, et al. (författare)
  • Serum testosterone is inversely, and sex hormone-binding globulin directly, associated with all-cause mortality in men.
  • 2021
  • Ingår i: The Journal of clinical endocrinology and metabolism. - : The Endocrine Society. - 1945-7197 .- 0021-972X. ; 106:2, s. e625-e637
  • Tidskriftsartikel (refereegranskat)abstract
    • Serum testosterone concentrations decline with age, while serum sex hormone-binding globulin (SHBG) concentrations increase.To analyse associations of baseline serum testosterone and SHBG concentrations, and calculated free testosterone (cFT) values, with all-cause and cause-specific mortality in men.The UK Biobank prospective cohort study of community-dwelling men 40-69 years-old, followed for 11 years.All-cause, atherosclerotic cardiovascular disease (CVD) and cancer-related mortality. Cox proportional hazards regression was performed, adjusting for age, waist circumference, medical conditions and other covariates. Models for testosterone included SHBG, and vice versa.In complete case analysis of 149,436 men with 10,053 deaths (1,925 CVD and 4,927 cancer-related), men with lower testosterone had higher mortality from any cause (lowest vs highest quintile, Q1 vs Q5, fully-adjusted hazard ratio [HR]=1.14, 95% confidence interval [CI]=1.06-1.22, overall trend P<0.001), and cancer (HR=1.20, CI=1.09-1.33, P<0.001), with no association for CVD deaths. Similar results were seen for cFT. Men with lower SHBG had lower mortality from any cause (Q1 vs Q5, HR=0.68, CI=0.63-0.73, P<0.001), CVD (HR=0.70, CI=0.59-0.83, P<0.001), and cancer (HR=0.80, CI=0.72-0.89, P<0.001). A multiply-imputed dataset (N=208,425, 15,914 deaths, 3,128 CVD and 7,468 cancer-related) and analysis excluding deaths within first two years (9,261, 1,734 and 4,534 events) yielded similar results.Lower serum testosterone is independently associated with higher all-cause and cancer-related, but not CVD-related, mortality in middle-aged to older men. Lower SHBG is independently associated with lower all-cause, CVD-related and cancer-related mortality. Confirmation and determination of causality requires mechanistic studies and prospective trials.
  •  
240.
  • Abrantes, João A., et al. (författare)
  • Elucidation of Factor VIII Activity Pharmacokinetics : A Pooled Population Analysis in Patients With Hemophilia A Treated With Moroctocog Alfa
  • 2017
  • Ingår i: Clinical Pharmacology and Therapeutics. - : Wiley. - 0009-9236 .- 1532-6535. ; 102:6, s. 977-988
  • Tidskriftsartikel (refereegranskat)abstract
    • This study investigated the disposition of coagulation factor VIII activity in 754 patients with moderate to severe hemophilia A following the administration of moroctocog alfa, a B-domain deleted recombinant factor VIII. Data analyzed included patients aged 1 day to 73 years enrolled in 13 studies conducted over a period of 20 years in 25 countries. A two-compartment population pharmacokinetic model with a baseline model described the pooled data well. Body size, age, inhibitors, race, and analytical assay were identified as significant predictors of factor VIII disposition. In addition, simulations of prophylactic dosing schedules in several pediatric cohorts showed large variability and suggest that younger patients would require higher weight-adjusted doses than adolescents to achieve target factor VIII trough activity when receiving every other day or twice weekly dosing.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 231-240 av 295
Typ av publikation
tidskriftsartikel (268)
forskningsöversikt (14)
konferensbidrag (10)
Typ av innehåll
refereegranskat (279)
övrigt vetenskapligt/konstnärligt (13)
Författare/redaktör
Adams, J. (16)
Hanson, K. (16)
Hultqvist, Klas (15)
Bohm, Christian (14)
Kolanoski, H. (14)
Sander, H. G. (14)
visa fler...
Koepke, L. (14)
Bai, X. (14)
Beattie, K. (14)
Landsman, H. (14)
Rizzo, A. (14)
Kowalski, M. (14)
Van Eijndhoven, N. (14)
Schlenstedt, S. (14)
Auffenberg, J. (14)
Bay, R. (14)
Berghaus, P. (14)
Berley, D. (14)
Bernardini, E. (14)
Bissok, M. (14)
Blaufuss, E. (14)
Braun, J. (14)
Christy, B. (14)
De Clercq, C. (14)
Desiati, P. (14)
DeYoung, T. (14)
Fadiran, O. (14)
Filimonov, K. (14)
Gallagher, J. (14)
Gerhardt, L. (14)
Gladstone, L. (14)
Goldschmidt, A. (14)
Grant, D. (14)
Ha, C. (14)
Walck, Christian (14)
Halzen, F. (14)
Helbing, K. (14)
Hickford, S. (14)
Hoshina, K. (14)
Huelsnitz, W. (14)
Hulth, Per Olof (14)
Hultqvist, K. (14)
Ishihara, A. (14)
Karg, T. (14)
Karle, A. (14)
Kiryluk, J. (14)
Kohnen, G. (14)
Kuwabara, T. (14)
Labare, M. (14)
Luenemann, J. (14)
visa färre...
Lärosäte
Karolinska Institutet (77)
Stockholms universitet (76)
Uppsala universitet (66)
Lunds universitet (34)
Göteborgs universitet (32)
Umeå universitet (20)
visa fler...
Chalmers tekniska högskola (12)
Kungliga Tekniska Högskolan (11)
Sveriges Lantbruksuniversitet (7)
Linköpings universitet (6)
Linnéuniversitetet (5)
Naturhistoriska riksmuseet (4)
Örebro universitet (3)
Södertörns högskola (2)
RISE (2)
Högskolan Kristianstad (1)
Högskolan i Halmstad (1)
Handelshögskolan i Stockholm (1)
Karlstads universitet (1)
visa färre...
Språk
Engelska (295)
Forskningsämne (UKÄ/SCB)
Naturvetenskap (139)
Medicin och hälsovetenskap (84)
Teknik (8)
Samhällsvetenskap (8)
Lantbruksvetenskap (3)
Humaniora (2)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy